Bionpharma Company Profile

What is the competitive landscape for BIONPHARMA

BIONPHARMA has seventy approved drugs.

There are five US patents protecting BIONPHARMA drugs.

There are ten patent family members on BIONPHARMA drugs in thirteen countries and one hundred and nineteen supplementary protection certificates in fifteen countries.

Summary for Bionpharma

International Patents:	10
US Patents:	5
Tradenames:	65
Ingredients:	60
NDAs:	70
Patent Litigation for Bionpharma:	See patent lawsuits for Bionpharma

Drugs and US Patents for Bionpharma

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bionpharma	CARBAMAZEPINE	carbamazepine	TABLET;ORAL	218221-001	Feb 16, 2024	AB	RX	No	No
Bionpharma	CEVIMELINE HYDROCHLORIDE	cevimeline hydrochloride	CAPSULE;ORAL	218290-001	Nov 8, 2023	AB	RX	No	No
Bionpharma	CIMETIDINE	cimetidine	TABLET;ORAL	218220-003	Nov 7, 2024	AB	RX	No	No
Bionpharma	DROXIDOPA	droxidopa	CAPSULE;ORAL	213033-003	Apr 28, 2021	AB	RX	No	No
Bionpharma	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE	granisetron hydrochloride	INJECTABLE;INJECTION	078863-002	Jun 30, 2008	AP	RX	No	No
Bionpharma	METHYLPHENIDATE HYDROCHLORIDE	methylphenidate hydrochloride	TABLET;ORAL	209753-001	Mar 2, 2018	AB	RX	No	No
Bionpharma	PROCHLORPERAZINE MALEATE	prochlorperazine maleate	TABLET;ORAL	217478-002	Apr 4, 2023	AB	RX	No	No

Expired US Patents for Bionpharma

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bionpharma	MIDOL LIQUID GELS	ibuprofen	CAPSULE;ORAL	021472-001	Oct 18, 2002	6,251,426

International Patents for Bionpharma Drugs

Country	Patent Number	Estimated Expiration
Canada	2600023
European Patent Office	1863458
European Patent Office	3061447
Hungary	E030784
Lithuania	1863458
Portugal	1863458
World Intellectual Property Organization (WIPO)	2006096580

Supplementary Protection Certificates for Bionpharma Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0994863	07C0037	France		PRODUCT NAME: MODIFICATION CRISTALLINE A DU RUFINAMIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/378/001 DU 20070116; REGISTRATION NO/DATE AT EEC: EU/1/06/378/001-016 DU 20070116
1613288	2011/027	Ireland		PRODUCT NAME: GILENYA-FINGOLIMOD; NAT REGISTRATION NO/DATE: EU/1/11/677/001 20110317; FIRST REGISTRATION NO/DATE: EU/1/11/677/002 17/03/2011 IRELAND EU/1/11/677/003 17/03/2011 IRELAND EU/1/11/677/004 20110317
2861072	2024C/512	Belgium		PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL, EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE (Y COMPRIS SOUS FORME HEMIHYDRATEE) ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210406
1020461	300482	Netherlands		PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMZOUT; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17091/0263 - 0001 20101105
0764174	C300159	Netherlands		PRODUCT NAME: COLESEVELAM, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/03/268/001 20040310
2782584	LUC00245	Luxembourg		PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210701
0914118	SPC/GB07/002	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/002 GRANTED TO NOVARTIS AG IN RESPECT OF THE PRODUCT DEFERASIROX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY 4-(3,5-BIS(2-HYDROXYPHENYL)-(1,2,4) TRIAZOL-L-YL) BENZOIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6179 DATED 24 OCTOBER 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 30 AUGUST 2021.

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Bionpharma

Pharmaceutical Competitive Landscape Analysis: Bionpharma – Market Position, Strengths & Strategic Insights

In the dynamic world of pharmaceuticals, Bionpharma has emerged as a notable player, carving out a unique position in the competitive landscape. This New Jersey-based company, founded in 2014 by former Ranbaxy executives, has rapidly grown to become a significant force in the generic pharmaceutical market[3]. Let's delve into Bionpharma's market position, strengths, and strategic insights to understand how this relatively young company is making waves in the industry.

Company Overview

Bionpharma specializes in developing and commercializing high-quality generic medications for both prescription and over-the-counter products[1]. The company's name, derived from the ancient Greek term "BIOS" meaning life, reflects its commitment to enhancing human health and well-being[2].

Core Business Areas

1. Generic Medications: Bionpharma focuses on developing and manufacturing generic drugs, which form the backbone of its product portfolio.

2. Over-the-Counter (OTC) Products: The company has a strong presence in the OTC market, offering various products directly to consumers.

3. Soft Gel Capsules: Bionpharma is one of the largest suppliers of soft gel capsules in the US, showcasing its manufacturing expertise[1].

4. E-commerce Presence: The company has established an online presence on Amazon for its OTC products, adapting to modern retail trends[1].

Market Position

Bionpharma has quickly established itself as a significant player in the generic pharmaceutical market. The company's strategic acquisitions and partnerships have played a crucial role in solidifying its market position.

Key Milestones

• 2015: Completed a transformative leveraged portfolio buy-out[1].
• 2016: Integrated the acquired portfolio into Bionpharma's commercial infrastructure[1].
• 2019: Expanded the Private Label OTC business to include all key retail chains as customers[1].
• 2021: Acquired OrBion Chennai, India, providing Bionpharma with a manufacturing facility and 28 ANDAs[1].

These milestones highlight Bionpharma's aggressive growth strategy and its ability to expand both organically and through acquisitions.

Strengths and Competitive Advantages

Bionpharma's rapid rise in the pharmaceutical industry can be attributed to several key strengths and competitive advantages.

1. Diverse Product Portfolio

Bionpharma manufactures, markets, and distributes over 50 drugs in the US and international markets[1]. This diverse portfolio includes:

• Generic prescription drugs
• Over-the-counter medications
• Soft gel capsules

The company's ability to offer a wide range of products allows it to cater to various market segments and reduces its dependence on any single product line.

2. Strong Manufacturing Capabilities

Bionpharma's manufacturing prowess is a significant strength. The company's OrBion facility in Chennai, India, boasts impressive capabilities:

• 4 state-of-the-art manufacturing modules
• 3 Packaging Suites (2 Blister and 1 Bottle)
• Installed capacity of 1.2 billion units (Tablets & Capsules)[5]

This robust manufacturing infrastructure enables Bionpharma to maintain control over its supply chain and ensure high-quality production.

3. Research and Development Focus

Bionpharma's commitment to innovation is evident in its research and development efforts. The company's NuWill site in Bangalore, India, serves as a comprehensive resource for:

• Formulation development
• Scaling processes
• Commercial production[7]

This focus on R&D allows Bionpharma to continually expand its product pipeline and stay competitive in the fast-evolving pharmaceutical landscape.

4. Strategic Partnerships

Bionpharma has established partnerships with global pharmaceutical companies, including Indian firms like Natco and Unimark Remedies[3]. These collaborations enable the company to:

• Access new technologies
• Expand its product offerings
• Enter new markets

Such partnerships are crucial for a relatively young company like Bionpharma to compete with established industry giants.

5. Experienced Leadership

The company was founded by five former Ranbaxy executives, bringing a wealth of industry experience to the table[3]. This seasoned leadership team provides Bionpharma with:

• Deep industry insights
• Strong network connections
• Strategic decision-making capabilities

Strategic Insights

Bionpharma's growth trajectory and market positioning offer several strategic insights for the pharmaceutical industry.

1. Importance of Diversification

Bionpharma's success underscores the importance of product diversification in the pharmaceutical industry. By offering a mix of generic drugs, OTC products, and specialized formulations, the company has created multiple revenue streams and reduced its risk exposure.

2. Value of Strategic Acquisitions

The company's rapid growth has been fueled in part by strategic acquisitions. In 2016, Bionpharma acquired a portfolio of approximately 25 products from Banner Life Sciences, significantly expanding its product offerings and revenue potential[3][6].

"The combined revenue of the acquired products is estimated at more than $70 million and forms a mix of high-potency steroidal, antiviral, neurology, over-the-counter pain management and anti-allergy medicines."[6]

This acquisition strategy has allowed Bionpharma to quickly gain market share and expand its capabilities.

3. Leveraging E-commerce Channels

Bionpharma's presence on Amazon for its OTC products demonstrates the growing importance of e-commerce in the pharmaceutical industry[1]. This strategy allows the company to reach consumers directly and adapt to changing purchasing behaviors.

4. Investing in Manufacturing Infrastructure

Bionpharma's significant investments in manufacturing infrastructure, particularly its OrBion facility, highlight the importance of controlling the production process. This approach allows the company to:

• Ensure product quality
• Control costs
• Respond quickly to market demands

5. Focus on High-Barrier Generic Products

Bionpharma's strategy includes developing and launching a pipeline of complementary high-barrier-to-entry generic products[1]. This approach allows the company to:

• Differentiate itself from competitors
• Potentially achieve higher profit margins
• Establish a stronger market position in specific product categories

Challenges and Future Outlook

Despite its impressive growth, Bionpharma faces several challenges in the highly competitive pharmaceutical landscape.

Challenges

1. Intense Competition: The generic drug market is highly competitive, with numerous established players and new entrants.

2. Regulatory Hurdles: Navigating the complex regulatory environment in the pharmaceutical industry remains a constant challenge.

3. Price Pressures: Generic drug manufacturers often face significant price pressures, which can impact profitability.

4. Technological Advancements: Keeping pace with rapid technological advancements in drug development and manufacturing is crucial for long-term success.

Future Outlook

Despite these challenges, Bionpharma's future outlook appears promising. The company's strategic focus on high-barrier generic products, investments in R&D and manufacturing capabilities, and diversified product portfolio position it well for continued growth.

The global biopharmaceuticals market is projected to grow from $421.58 billion in 2024 to $1,369 billion in 2034, with a healthy CAGR of 12.5%[8]. This growth presents significant opportunities for companies like Bionpharma to expand their market presence and introduce innovative products.

Key Takeaways

1. Bionpharma has rapidly established itself as a significant player in the generic pharmaceutical market through strategic acquisitions and partnerships.

2. The company's diverse product portfolio, strong manufacturing capabilities, and focus on R&D are key strengths that contribute to its competitive advantage.

3. Bionpharma's success highlights the importance of product diversification, strategic acquisitions, and investments in manufacturing infrastructure in the pharmaceutical industry.

4. The company's focus on high-barrier generic products and e-commerce presence demonstrates its adaptability to market trends and changing consumer behaviors.

5. While facing challenges such as intense competition and regulatory hurdles, Bionpharma's strategic positioning and the growing biopharmaceuticals market present opportunities for continued growth and success.

FAQs

1. Q: When was Bionpharma founded? A: Bionpharma was founded in 2014 by five former Ranbaxy executives[3].

2. Q: What are Bionpharma's main product categories? A: Bionpharma specializes in generic medications, over-the-counter products, and soft gel capsules[1].

3. Q: Where are Bionpharma's manufacturing facilities located? A: Bionpharma's main manufacturing facility, OrBion, is located in Chennai, India[5].

4. Q: How many drugs does Bionpharma manufacture and distribute? A: Bionpharma manufactures, markets, and distributes over 50 drugs in the US and international markets[1].

5. Q: What was a significant acquisition made by Bionpharma? A: In 2016, Bionpharma acquired a portfolio of approximately 25 products from Banner Life Sciences, estimated to have a combined revenue of more than $70 million[3][6].

Sources cited: [1] https://bionpharma.com/about-phrmacy/ [2] https://bionpharma.com [3] http://www.signethealthcarepartners.com/news/2016/5/5/bionpharma-buys-25-products-from-specialty-drug-maker-banner-life-sciences [5] https://bionpharma.com/manufacturing/ [6] https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bionpharma-buys-25-products-from-specialty-drug-maker-banner-life-sciences/articleshow/50261016.cms [7] https://bionpharma.com/research-and-development/ [8] https://www.towardshealthcare.com/insights/biopharmaceuticals-market-is-rising-rapidly